RS65851B1 - Upotreba antagonista il-17 za inhibiciju progresije strukturalnog oštećenja kod pacijenata sa psorijatičnim artritisom - Google Patents

Upotreba antagonista il-17 za inhibiciju progresije strukturalnog oštećenja kod pacijenata sa psorijatičnim artritisom

Info

Publication number
RS65851B1
RS65851B1 RS20240773A RSP20240773A RS65851B1 RS 65851 B1 RS65851 B1 RS 65851B1 RS 20240773 A RS20240773 A RS 20240773A RS P20240773 A RSP20240773 A RS P20240773A RS 65851 B1 RS65851 B1 RS 65851B1
Authority
RS
Serbia
Prior art keywords
secukinumab
patient
seq
antibody
week
Prior art date
Application number
RS20240773A
Other languages
English (en)
Serbian (sr)
Inventor
Shephard Mpofu
Hanno Richards
Gregory Ligozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54186247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS65851(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of RS65851B1 publication Critical patent/RS65851B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)
RS20240773A 2014-09-10 2015-09-08 Upotreba antagonista il-17 za inhibiciju progresije strukturalnog oštećenja kod pacijenata sa psorijatičnim artritisom RS65851B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048512P 2014-09-10 2014-09-10
EP15767597.6A EP3191120B1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
PCT/IB2015/056871 WO2016038538A1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Publications (1)

Publication Number Publication Date
RS65851B1 true RS65851B1 (sr) 2024-09-30

Family

ID=54186247

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20240773A RS65851B1 (sr) 2014-09-10 2015-09-08 Upotreba antagonista il-17 za inhibiciju progresije strukturalnog oštećenja kod pacijenata sa psorijatičnim artritisom

Country Status (22)

Country Link
US (2) US11278618B2 (cg-RX-API-DMAC7.html)
EP (2) EP4406969A3 (cg-RX-API-DMAC7.html)
JP (4) JP2017528465A (cg-RX-API-DMAC7.html)
KR (2) KR20230170796A (cg-RX-API-DMAC7.html)
CN (4) CN115944734A (cg-RX-API-DMAC7.html)
AU (2) AU2015313827C1 (cg-RX-API-DMAC7.html)
BR (1) BR112017003332A2 (cg-RX-API-DMAC7.html)
CA (1) CA2960754A1 (cg-RX-API-DMAC7.html)
DK (1) DK3191120T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981697T3 (cg-RX-API-DMAC7.html)
FI (1) FI3191120T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240921T1 (cg-RX-API-DMAC7.html)
HU (1) HUE067081T2 (cg-RX-API-DMAC7.html)
LT (1) LT3191120T (cg-RX-API-DMAC7.html)
MX (1) MX2017003216A (cg-RX-API-DMAC7.html)
PL (1) PL3191120T3 (cg-RX-API-DMAC7.html)
PT (1) PT3191120T (cg-RX-API-DMAC7.html)
RS (1) RS65851B1 (cg-RX-API-DMAC7.html)
RU (1) RU2697383C2 (cg-RX-API-DMAC7.html)
SI (1) SI3191120T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400285T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016038538A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2960754A1 (en) * 2014-09-10 2016-03-17 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
CA3001260A1 (en) 2015-10-27 2017-05-04 Ucb Biopharma Sprl Methods of treatment using anti-il-17a/f antibodies
TW201842933A (zh) * 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
WO2019040230A1 (en) * 2017-08-23 2019-02-28 Eli Lilly And Company TREATMENT OF GENITAL PSORIASIS
CA3080665A1 (en) * 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17) antagonists
EP3980065A4 (en) * 2019-06-04 2023-07-05 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATMENT OF PSORIAL ARTHRITIS WITH ANTI-IL23 SPECIFIC ANTIBODY
KR102576258B1 (ko) 2019-12-05 2023-09-11 아주대학교산학협력단 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 조성물 및 이의 의학적 용도
KR102394378B1 (ko) 2020-10-14 2022-05-03 한림대학교 산학협력단 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PT1963368E (pt) 2005-12-13 2012-09-14 Lilly Co Eli Anticorpos anti-il-17
WO2007117749A2 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies fpr treating cancer
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
WO2008156865A2 (en) 2007-06-20 2008-12-24 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US7856118B2 (en) 2007-07-20 2010-12-21 The Procter & Gamble Company Methods for recommending a personal care product and tools therefor
UA103499C2 (ru) 2008-09-29 2013-10-25 Рош Глікарт Аг Антитело против интерлейкина-17 (ил-17) человека и его применение
JP5537740B2 (ja) * 2010-10-08 2014-07-02 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法
EP4116325A1 (en) * 2010-11-05 2023-01-11 Novartis AG Methods of treating rheumatoid arthritis using il-17 antagonists
WO2012082573A1 (en) * 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
RU2014125071A (ru) * 2011-11-21 2015-12-27 Новартис Аг Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa
CN103936854B (zh) * 2014-04-30 2016-08-17 北京精益泰翔技术发展有限公司 抗il-17a单克隆抗体及其制备与应用
CA2960754A1 (en) * 2014-09-10 2016-03-17 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Also Published As

Publication number Publication date
EP4406969A2 (en) 2024-07-31
AU2018201410A1 (en) 2018-03-22
MX2017003216A (es) 2017-05-23
AU2015313827C1 (en) 2018-08-30
LT3191120T (lt) 2024-07-25
KR20170045240A (ko) 2017-04-26
HUE067081T2 (hu) 2024-09-28
ES2981697T3 (es) 2024-10-10
AU2015313827A1 (en) 2017-02-16
JP2021152021A (ja) 2021-09-30
PL3191120T3 (pl) 2024-08-26
JP2023109973A (ja) 2023-08-08
CN113069542A (zh) 2021-07-06
RU2017107501A3 (cg-RX-API-DMAC7.html) 2019-03-12
SMT202400285T1 (it) 2024-09-16
JP7288927B2 (ja) 2023-06-08
US20170281762A1 (en) 2017-10-05
HRP20240921T1 (hr) 2024-10-11
EP4406969A3 (en) 2024-11-27
FI3191120T3 (fi) 2024-07-10
CA2960754A1 (en) 2016-03-17
CN115944734A (zh) 2023-04-11
CN107073110A (zh) 2017-08-18
KR20230170796A (ko) 2023-12-19
US11278618B2 (en) 2022-03-22
RU2017107501A (ru) 2018-10-10
EP3191120A1 (en) 2017-07-19
AU2015313827B2 (en) 2018-02-15
BR112017003332A2 (pt) 2017-11-28
DK3191120T3 (da) 2024-07-15
JP7591092B2 (ja) 2024-11-27
JP2025024104A (ja) 2025-02-19
CN115957326A (zh) 2023-04-14
WO2016038538A1 (en) 2016-03-17
US20220313818A1 (en) 2022-10-06
EP3191120B1 (en) 2024-04-10
JP2017528465A (ja) 2017-09-28
RU2697383C2 (ru) 2019-08-13
PT3191120T (pt) 2024-07-16
SI3191120T1 (sl) 2024-10-30

Similar Documents

Publication Publication Date Title
US20220313818A1 (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritic patients
TWI604851B (zh) Ｉｌ－１７抗體用於製備治療強直性脊椎炎之藥物之用途
JP7389077B2 (ja) インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
JP2025169269A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して自己免疫疾患を治療する方法
HK40110169A (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients